1. Home
  2. ENVX vs TRVI Comparison

ENVX vs TRVI Comparison

Compare ENVX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovix Corporation

ENVX

Enovix Corporation

HOLD

Current Price

$6.93

Market Cap

1.4B

Sector

Miscellaneous

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$14.74

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENVX
TRVI
Founded
2006
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
ENVX
TRVI
Price
$6.93
$14.74
Analyst Decision
Buy
Strong Buy
Analyst Count
9
11
Target Price
$13.61
$21.55
AVG Volume (30 Days)
5.2M
1.7M
Earning Date
05-13-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
40.94
31.91
EPS
N/A
N/A
Revenue
$31,821,000.00
N/A
Revenue This Year
$30.37
N/A
Revenue Next Year
$238.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
37.91
N/A
52 Week Low
$4.67
$5.38
52 Week High
$16.49
$16.12

Technical Indicators

Market Signals
Indicator
ENVX
TRVI
Relative Strength Index (RSI) 58.91 59.84
Support Level $6.68 $10.07
Resistance Level $8.66 $16.12
Average True Range (ATR) 0.44 0.76
MACD -0.00 -0.05
Stochastic Oscillator 61.94 70.31

Price Performance

Historical Comparison
ENVX
TRVI

About ENVX Enovix Corporation

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, the United States, Norway, Taiwan, and other regions.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: